title: Quantification of angiogenesis in estrogen receptor-positive and negative breast carcinoma.
abstract: BACKGROUND
  The objective of this study was to evaluate angiogenesis according to CD34 antigen expression in estrogen receptor (ER)-positive and negative breast carcinomas.
  
  
  METHODS
  This study comprised 64 cases of infiltrating ductal carcinoma in postmenopausal women divided into two groups: Group A: ER-positive, n = 35; and Group B: ER-negative, n = 29. The anti-CD34 monoclonal antibody was used as a marker for endothelial cells. Microvessel count was carried out in 10 fields per slide using a 40x objective lens (magnification 400x). Statistical analysis of the data was performed using Student's t-test (p < 0.05).
  
  
  RESULTS
  The mean number of vessels stained with the anti-CD34 antibody in the estrogen receptor-positive and negative tumors was 23.51 +/- 1.15 and 40.24 +/- 0.42, respectively. The number of microvessels was significantly greater in the estrogen receptor-negative tumors (p < 0.001).
  
  
  CONCLUSIONS
  ER-negative tumors have significantly greater CD34 antigen expression compared to ER-positive tumors.
authors: Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil. beneditoborges@globo.com.
authors: Jb
authors: J
authors: Parentes-Vieira
authors: Pv
authors: P
authors: Lopes-Costa
authors: Cg
authors: C
authors: Pires
authors: Ar
authors: A
authors: Dos Santos
authors: Jd
authors: J
authors: Pereira-Filho
authors: Bb
authors: B
authors: da Silva
references: Arch Pathol Lab Med. 2000 Jul;124(7):966-78
references: 10888772
references: J Surg Oncol. 2005 May 1;90(2):77-80
references: 15844191
references: Mod Pathol. 2005 Mar;18(3):374-81
references: 15578079
references: Cancer Treat Res. 1988;40:119-65
references: 2908648
references: Cancer Res. 1995 Sep 1;55(17):3902-7
references: 7641210
references: Nat Med. 1995 Jan;1(1):27-31
references: 7584949
references: N Engl J Med. 1995 Dec 28;333(26):1757-63
references: 7491141
references: Breast Cancer Res Treat. 2001 Mar;66(1):9-15
references: 11368415
references: Cancer Res. 1974 May;34(5):997-1004
references: 4841969
references: Trends Pharmacol Sci. 1998 Jun;19(6):216-22
references: 9666712
references: Cancer Res. 2000 Dec 15;60(24):7094-8
references: 11156416
references: Eur J Endocrinol. 2004 Mar;150(3):243-55
references: 15012607
references: Rom J Morphol Embryol. 2007;48(1):25-31
references: 17502947
references: Breast Cancer Res Treat. 2006 Jan;95(1):37-43
references: 16267616
references: Breast Cancer Res Treat. 2003 Sep;81(2):159-68
references: 14572158
references: N Engl J Med. 1991 Jan 3;324(1):1-8
references: 1701519
references: Mod Pathol. 2005 Jan;18(1):26-35
references: 15332092
references: Clin Cancer Res. 2002 Jun;8(6):1816-21
references: 12060622
references: Am J Pathol. 1991 Apr;138(4):867-73
references: 2012175
references: Tumori. 2005 Jan-Feb;91(1):46-52
references: 15850004
references: Breast Cancer Res Treat. 1990 Feb;15(2):109-17
references: 2322649
references: Anticancer Res. 2001 Nov-Dec;21(6B):4325-31
references: 11908687
references: Circulation. 1997 Mar 18;95(6):1505-14
references: 9118519